Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

Sergio Rizzo; Giuseppe Bronte; Daniele Fanale; Lidia Corsini; Nicola Silvestris; Daniele Santini; Gaspare Gulotta; Viviana Bazan; Nicola Gebbia; Fabio Fulfaro

doi:10.1016/S0305-7372(10)70021-9

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

Identifier:nobleid.org/w1/20260515/6A86552B

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/6A86552B.svg?ark=w1%2F20260515%2F6A86552B)](https://nobleid.org/work/w1/20260515/6A86552B)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

Identifier:nobleid.org/w1/20260515/6A86552B

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/6A86552B.svg?ark=w1%2F20260515%2F6A86552B)](https://nobleid.org/work/w1/20260515/6A86552B)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work